B-5354c is a new inhibitor of sphingosine kinase from a novel marine bacterium, SANK 71896. Kinetic study revealed that B-5354c inhibits sphingosine kinase with a Ki value of 12/im. The inhibition is noncompetitive with respect to sphingosine. The compound also inhibits sphingosine-1-phosphate formation in human platelets. Experiments using synthetic derivatives of B-5354c indicate that all the three functional groups, i.e., the long unsaturated aliphatic chain, 4-amino and 3-hydroxyl groups are necessary to inhibit sphingosine kinase.
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The metabolic product of sphingosine (SPH) kinase, SPH-1-phosphate (SPP) is a bioactive sphingolipid metabolite which has diverse biological functions. It acts as a second messenger to regulate proliferation and survival intracellulary, and as a ligand for G protein-coupled receptors of the Edg-1 sub family extracellularly1 '2Ŝ PP levels are mainly dependent on the activity of SPH kinase, but the precise regulation mechanisms of the enzyme remain unclear. Since low molecular weight inhibitors will be powerful tools to analyze the functions of the enzyme, we screened for inhibitors of SPHkinase in natural extracts and found new SPH kinase inhibitors; B-5354a, b and c (B-5354s, Fig. 1 ) in the culture broth of a novel marine bacterium, SANK71896. In the preceding paper3), we described the taxonomy of SANK71896, and the fermentation, isolation, physico-chemical properties and structure determination of the B-5354s.
D,L-r/zreo-dihydro-SPH and AyV-dimethyl-SPH (DMS) were reported to inhibit SPH kinase in /hm order4'5), however they also have been reported to have several physiological functions besides the inhibition of SPH kinase probably on account of their structural similarity to SPH. For example, DMS acts as a potent inhibitor of PKC6'7) and it induces apoptosis in a variety of human cell lines8). On the other hand, B-5354s, esters of 4-amino-3-hydroxybenzoic acid, are not structural analogs of SPH. Hence, the B-5354s are expected not to exhibit such pp.759 -764 unfavorable activities observed in SPH analogs. To shed light on the characteristics of B-5354s, we made some biological evaluations including kinetic analysis, enzyme inhibition in platelets and investigation of the inhibition specificity with focus on B-5354c that is the major component in the fermentation broth. In this paper, we report these results along with structure-activity relationships of the compound.
Materials and Methods
Material s
[3-3U]D-Erythro-SV¥L (20 Ci/mmol) was purchased from Du Pont-New England Nuclear. SPH and SPH-1 -phosphate (SPP) were from Matreya. ATTV-DimethylSPH (DMS) was from Calbiochem. The 4-amino-3-hydroxybenzoic acid (3 in Fig. 1 ) and di-tert-butyl dicarbonate were from Tokyo Chemical Industry. B-5354a, b and c were prepared as described in the preceding paper3).
SPH Kinase Assay in a Cell-free System As a source of SPHkinase, we used rat liver cytosol as previously described9). For the assay of SPHkinase activity in a cell-free system, we used the method of Louie et aLl0)
with some modifications as previously described9). [ di-tert-butyl dicarbonate and 5 mlà" of pyridine were added. The reaction mixture was stirred for 1 hour at room temperature. After aqueous workup and extraction with EtOAc, 1.5 g of iV-Boc-4-amino-3-hydroxybenzoic acid was obtained. To a solution of ALBoc-4-amino-3-hydroxybenzoic acid (25mg) and 4-dimethyl-aminopyridine (8mg) in 2ml of 7?-BuOH, 40mg of dicyclohexylcarbodimide dissolved in 1 ml of n-BuOH was added. The reaction mixture was stirred for 2 hours at room temperature, and then 5ml of H2O was added. After removing n-BxxOHunder vacuo, the resulting aqueous solution was extracted with EtOAc and the extract was washed with brine, dried over Na2SO4and concentrated in 7V-Acetyl-B-5354c (4): 4 was prepared by ]V-acetylation ofB-5354c as described in a previous paper3). (5): To a solution ofB-5354c (1 1 mg) in 2ml of CH2C12, excess amount of diazomethane dissolved in ethylether was added. * IC50 value {m M) in a cell-free assay system using rat liver cytosol as the enzyme source.
** SPP/SPH ratio (% inhibition at 30 ul g/ml).
SPH Kinase Inhibition in HumanPlatelets
We As shown in Fig. 4 , B-5354c inhibited the SPP formation in a dose-dependent manner even when added extracellularly, suggesting that B-5354c permeates the plasma membrane and inhibits SPHkinase in intact cells. In a control study, DMS also inhibited the SPP formation.
Specificity of B-5354c
In order to assess the specificity of B-5354c, we evaluated the effects of the compound on other sphingolipid metabolic enzyme, neutral SMase and on other kinases, PI 3-kinase and PKC. B-5354c virtually showed no inhibitory activity towards these enzymes at 500^M. These results indicate that B-5354c is a specific inhibitor for SPH kinase. AUG. 2000 Structure-activity Relationships B-5354c is a di-substituted benzoic acid ester with unsaturated alcohol. To access which functionality may contribute to the inhibitory activity, derivatives of B-5354c, 1-5, were prepared (Fig. 1) . The activities of these compounds along with the natural products were summarized in Table 1 . The amino group and the phenolic hydroxyl group were essential for the activity since TV-acetate (4) and methyl ester (5) were devoid of the activity. It is noteworthy that unsaturation in the aliphatic side chain was necessary for enzyme inhibition since the derivative bearing a saturated side chain, 1 was inactive at 500^M. Derivatives with a short side chain (2) and without an aliphatic chain (3) were also inactive. Among the natural products, slight deviation in inhibitory activity was observed maybe reflecting length and number of unsaturated bonds in the aliphatic chain.
In summary,this study indicates that polar head group with an amino and a hydroxyl group as well as an unsaturated aliphatic chain is required for the enzyme inhibition of B-5354c. 
Discussion
In the present study, we have confirmed that B-5354c is a specific and noncompetitive inhibitor of SPHkinase. These results suggest that B-5354c may interact with a domain distinct from the SPHbinding site and regulate the enzyme activity. There are many reports that SPHkinase activities are regulated by growth factors or cytokines, such as platelet-derived growth factor13), nerve growth factor14) and tumor necrosis factor-a15). Since SPHkinases are activated transiently within a short time after those stimuli13~15), the kinase activities might be regulated by post-translational mechanisms such as protein-protein interaction or phosphorylation.
The precise regulation mechanisms of SPH kinase remain unclear, hence B-5354c may be a useful tool to study the mechanisms.
Concerning the noncompetitive regulation of SPH kinase, it was reported that phosphatidylserine (PS) enhances SPH kinase activity in a noncompetitive manner16). Interestingly, PS also needs double bonds in its aliphatic chain to regulate SPH kinase activity just like B-5354c, which we have reported here. Therefore, the double bond in the aliphatic chain of B-5354c may be necessary to interact with SPH kinase or its substrate, SPH. B-5354c reduces SPP formation in platelets with a dose response similar to that in the cell-free system (Fig. 2, 4) . 
